SANOFI INDIA LIMITED

Sanofi India Limited held an Investor Conference Call on August 5, 2026, to discuss its financial results for the quarter and half year ended June 30, 2026. Management reported a strong performance in the diabetes business, achieving nearly 14% growth, driven by products like Toujeo and Soliqua. The company emphasized its market leadership in the diabetes segment, holding a 47% market share by value. Management also highlighted a 2% growth in overall performance compared to the previous year, attributing this to strategic partnerships and resource optimization. The call included discussions on the company's CSR initiatives, which aim to reach over 600,000 beneficiaries by year-end. Financially, the company reported a 19% increase in profit before tax for the quarter. However, management acknowledged challenges in the partnership business, particularly in the cardiovascular and CNS segments, and indicated ongoing efforts to improve performance in these areas.

The management highlighted strong growth in the diabetes segment while also addressing challenges in other areas.